arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

BioAge Labs, Inc.

BIOA Health Care Biotechnology: Pharmaceutical Preparations
$5.10
▼ -7.4% Today
as of Oct 23, 16:46 ET
Last 30 days -39.86% Sep 14 → Oct 23
$4.55 $5.60 $6.66 $7.72 $8.77 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$5.48
High
$5.48
Low
$5.05
Volume
$464,221
Avg Vol
$652,759
Mkt Cap
$287M
P/E (TTM)
—
Beta
—
52w High
$25.95
52w Low
$4.81
Div Yield
—
Shares Out
$46M

Recent Press Releases & News last 60 days · 6 items

Oct 14 · 12:42 MT Newswires
BioAge Labs, Deep Origin Collaborate on AI-Driven Drug Discovery
Oct 12 · 17:02 MT Newswires
BioAge Labs' Lead Drug Faces Uncertain Path as Data Looms, UBS Says
Sep 25 · 20:30 PR GlobeNewswire
BioAge Labs to Present at Upcoming Investor Conferences
▸ Show all 6 press releases & news Free account →

BIOA earnings at a glance

BioAge Labs, Inc. (BIOA) is scheduled to report earnings on Thursday, November 5, 2026 — in 12 days. Analysts expect earnings per share of -$0.66, compared with -$0.56 in the same quarter last year (-18%). The options market is pricing a move of about ±82.9% after the report, a range of roughly $0.87 to $9.33 from today's $5.10. Over its last 6 reports the stock rose the next day 3 times and fell 3, moving ±3.8% on average; after the most recent report on Aug 5, 2026 it moved +2.6%. That means options currently expect more movement than BIOA has typically delivered. BIOA beat the consensus EPS estimate in 5 of its last 6 reported quarters. Implied volatility is currently 7%. The share price of $5.10 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$4.81
$26
1% of range
Avg surprise (last 6)
+15.1%
Avg reaction (last 6)
-1.7%
50% positive
Latest IV / EM
702%
EM ±82.9% · $5 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-8.74$-6.64$-4.55$-2.46$-0.36 Actual $-8.74Actual $-7.76Actual $-7.94Actual $-6.70Actual $-0.36Est $-0.52Actual $-0.60Est $-0.56Actual $-0.56Est $-0.67Actual $-0.72Est $-0.83Actual $-0.52Est $-0.71Actual $-0.58Est $-0.65 SepMarJunSepMar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-26M$-19M$-12M$-4M$3M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Wed Aug 5, 2026Jun/2026 $-0.58 $-0.65 +10.8% -8.3% +2.6% earnings
Fri May 8, 2026Mar/2026 $-0.52 $-0.71 +26.8% -44.4% +1.0% earnings
Tue Mar 24, 20268K 2026-03-24 $-0.72 $-0.83 +13.2% — -13.5% earnings
Thu Nov 6, 2025Sep/2025 $-0.56 $-0.67 +16.4% — -2.8% earnings
Wed Aug 6, 2025Jun/2025 $-0.60 $-0.56 -7.1% — -0.2% earnings
Tue May 6, 2025Mar/2025 $-0.36 $-0.52 +30.8% — +2.8% earnings
Mon Sep 30, 2024Sep 2024 $-6.70 — — — — financials
Sun Jun 30, 2024Jun 2024 $-7.94 — — — — financials
Sun Mar 31, 2024Mar 2024 $-7.76 — — — — financials
Sat Sep 30, 2023Sep 2023 $-8.74 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Thu Nov 5, 2026Sep/2026OTHER -$0.66-$0.56 -17.9%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$2M$3M—$2M$2M$1M—$0
Cost of revenue————————
Gross profit————————
Operating income$-29M$-25M—$-23M$-25M$-16M—$-25M
Net income$-26M$-22M—$-20M$-22M$-13M—$-23M
EPS (diluted)$-0.58$-0.52—$-0.56$-0.60$-0.36—$-6.70

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$74M$242M$189M$216M$220M$257M$354M$334M
Inventory————————
Total current assets$330M$392M$287M$291M$302M$325M$357M$336M
Total assets$397M$398M$295M$305M$322M$344M$358M$337M
Long-term debt———$0$0$1M$3M$4M
Total liabilities$22M$19M$23M$28M$27M$31M$35M$24M
Total equity$375M$379M$272M$277M$295M$313M$323M$314M

Implied volatility — last 90 days

39%244%450%656%861% Jun 07 — IV 39% · EM ±5.4%Jun 08 — IV 164% · EM ±21.7%Jun 09 — IV 53% · EM ±6.6%Jun 10 — IV 163% · EM ±19.2%Jun 11 — IV 322% · EM ±35.6%Jun 15 — IV 202% · EM ±14.6%Jun 16 — IV 153% · EM ±9.0%Jun 19 — IV 118% · EM ±26.0%Jun 22 — IV 99% · EM ±20.6%Jun 23 — IV 91% · EM ±18.6%Jun 24 — IV 101% · EM ±20.3%Jun 25 — IV 103% · EM ±20.2%Jun 26 — IV 98% · EM ±18.8%Jun 29 — IV 107% · EM ±19.0%Jun 30 — IV 104% · EM ±18.0%Jul 01 — IV 108% · EM ±18.0%Jul 02 — IV 108% · EM ±17.5%Jul 03 — IV 114% · EM ±17.8%Jul 06 — IV 126% · EM ±17.5%Jul 07 — IV 140% · EM ±18.4%Jul 08 — IV 158% · EM ±19.8%Jul 09 — IV 105% · EM ±12.4%Jul 10 — IV 152% · EM ±16.7%Jul 13 — IV 142% · EM ±11.8%Jul 14 — IV 138% · EM ±10.0%Jul 15 — IV 162% · EM ±9.6%Jul 16 — IV 213% · EM ±8.9%Jul 20 — IV 193% · EM ±45.7%Jul 21 — IV 188% · EM ±43.7%Jul 22 — IV 197% · EM ±45.1%Jul 23 — IV 205% · EM ±46.1%Jul 24 — IV 224% · EM ±49.5%Jul 27 — IV 237% · EM ±49.6%Jul 28 — IV 219% · EM ±44.7%Jul 29 — IV 228% · EM ±45.7%Jul 30 — IV 253% · EM ±49.5%Jul 31 — IV 119% · EM ±22.8%Aug 03 — IV 89% · EM ±15.7%Aug 04 — IV 155% · EM ±26.8%Aug 05 — IV 95% · EM ±15.9%Aug 06 — IV 99% · EM ±16.0%Aug 07 — IV 101% · EM ±15.8%Aug 10 — IV 173% · EM ±24.0%Aug 11 — IV 87% · EM ±11.5%Aug 12 — IV 94% · EM ±11.7%Aug 13 — IV 81% · EM ±9.6%Aug 14 — IV 145% · EM ±16.0%Aug 17 — IV 92% · EM ±7.7%Aug 18 — IV 185% · EM ±13.4%Aug 20 — IV 134% · EM ±5.6%Aug 24 — IV 66% · EM ±13.8%Aug 25 — IV 57% · EM ±11.7%Aug 26 — IV 56% · EM ±11.2%Aug 27 — IV 60% · EM ±11.7%Aug 28 — IV 57% · EM ±10.9%Aug 31 — IV 82% · EM ±14.5%Sep 01 — IV 52% · EM ±8.9%Sep 02 — IV 160% · EM ±26.7%Sep 03 — IV 81% · EM ±13.2%Sep 08 — IV 40% · EM ±5.2%Sep 09 — IV 170% · EM ±21.3%Sep 10 — IV 252% · EM ±29.8%Sep 11 — IV 288% · EM ±31.8%Sep 14 — IV 371% · EM ±31.0%Sep 15 — IV 862% · EM ±62.3%Sep 17 — IV 503% · EM ±21.0%Sep 21 — IV 68% · EM ±14.2%Sep 22 — IV 71% · EM ±14.5%Sep 23 — IV 63% · EM ±12.7%Sep 24 — IV 89% · EM ±17.3%Sep 25 — IV 91% · EM ±17.4%Sep 28 — IV 98% · EM ±17.4%Sep 29 — IV 106% · EM ±18.2%Sep 30 — IV 93% · EM ±15.5%Oct 01 — IV 154% · EM ±25.0%Oct 02 — IV 189% · EM ±29.5%Oct 06 — IV 349% · EM ±46.1%Oct 07 — IV 325% · EM ±40.7%Oct 08 — IV 702% · EM ±82.9%

Sector peers

ABEO
Abeona Therapeutics Inc.
$286M $4.40-2.4%
INDP
Indaptus Therapeutics, Inc.
$282M $3.160.0%
PRLD
Prelude Therapeutics Incorporated
$302M $3.63-0.6%
BCYC
Bicycle Therapeutics plc
$261M $3.55-0.6%
AMRN
Amarin Corporation plc
$254M $11.79+2.4%
IFRX
InflaRx N.V.
$252M $1.56+0.7%

BIOA earnings FAQ

When is BIOA's next earnings date?

BioAge Labs, Inc. is expected to report on November 5, 2026.

What is BIOA's expected move for earnings?

Options currently price a move of about ±82.9%, or $4.23 per share either way from $5.10.

How does BIOA stock usually react to earnings?

Across the last 6 reports the average next-day move was ±3.8%, up 3 times and down 3 times.

What EPS are analysts expecting from BioAge Labs, Inc.?

The consensus estimate is -$0.66 per share, versus -$0.56 a year ago.

What is BIOA's implied volatility?

BIOA's at-the-money implied volatility is about 7% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in